ANTISENSE-BASED EXON SKIPPING AS A THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY, STATUS AND PROSPECTS

被引：0

作者：

van Ommen, G. -J. ^{[1
]}

Aartsma-Rus, A. ^{[1
]}

Evers, M. ^{[1
]}

van Roon, W. ^{[1
]}

'tHoen, P. -B. ^{[1
]}

Kemaladewi, D. ^{[1
]}

Verbeek, S. ^{[1
]}

Yllmaz-Elis, S. ^{[1
]}

Dauwerse, H. ^{[2
]}

Lesnik-Oberstein, S. ^{[2
]}

den Dunnen, J. T. ^{[1
]}

Goemans, N. ^{[3
]}

Tulinus, M. ^{[4
]}

Verschuuren, J. ^{[5
]}

de Kimpe, S. ^{[6
]}

Campion, G. ^{[6
]}

van Deutekom, J. ^{[6
]}

机构：

[1] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands

[2] Leiden Univ, Dept Clin Genet, Med Ctr, Leiden, Netherlands

[3] Univ Hosp Leuven, Dept Pediat Neurol, Louvain, Belgium

[4] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden

[5] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands

[6] Prosensa Therapeut, Leiden, Netherlands

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2011年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：7 / 7

页数：1

共 50 条

[31] Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations
Aartsma-Rus, Annemieke
Fokkema, Ivo
Verschuuren, Jan
Ginjaar, Leke
van Deutekom, Judith
van Ommen, Gert-Jan
den Dunnen, Johan T.
HUMAN MUTATION, 2009, 30 (03) : 293 - 299
[32] Comparative analysis of antisense oligonucleotide analogs for targeted exon skipping in Duchenne muscular dystrophy
Aartsma-Rus, A
Hoen, PAC
Kaman, WE
Bremmer-Bout, M
Janson, AM
den Dunnen, JT
van Ommen, GJB
van Deutekom, JCT
NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 613 - 613
[33] Systemic Antisense-Mediated Exon Skipping in Mouse Models for Duchenne Muscular Dystrophy
Aartsma-Rus, Annemieke
Heemskerk, Hans
De Winter, Christa
Van Putten, Maaike
Janson, Anneke
Verschuuren, Jan
Den Dunnen, Johan
Van Deutekom, Judith
Van Ommen, Gert-Jan
MOLECULAR THERAPY, 2009, 17 : S166 - S166
[34] Optimization of antisense-mediated exon skipping in mouse models for Duchenne muscular dystrophy
Aartsma-Rus, A.
Heemskerk, H. A.
de Winter, C. L.
van Putten, M.
De Kimpe, S.
van Deutekom, J. C. T.
van Ommen, G. J. B.
NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 757 - 757
[35] Nanoparticle Delivery of Antisense Oligonucleotides and Their Application in the Exon Skipping Strategy for Duchenne Muscular Dystrophy
Falzarano, Maria Sofia
Passarelli, Chiara
Ferlini, Alessandra
NUCLEIC ACID THERAPEUTICS, 2014, 24 (01) : 87 - 100
[36] Beyond clinical trials for antisense-mediated exon skipping for Duchenne muscular dystrophy
Aartsma-Rus, Annemieke
HUMAN GENE THERAPY, 2014, 25 (11) : A13 - A13
[37] In vivo studies on antisense-induced exon skipping: towards a gene correction therapy for Duchenne muscular dystrophy
van Deutekom, JCT
Bremmer-Bout, M
Kaman, WE
den Dunnen, JT
van Ommen, GJ
NEUROMUSCULAR DISORDERS, 2002, 12 (7-8) : 782 - 782
[38] Exon-skipping advances for Duchenne muscular dystrophy
Echevarria, Lucia
Aupy, Philippine
Goyenvalle, Aurelie
HUMAN MOLECULAR GENETICS, 2018, 27 (R2) : R163 - R172
[39] Clinical trials of exon skipping in Duchenne muscular dystrophy
Mendell, Jerry R.
Sahenk, Zarife
Rodino-Klapac, Louise R.
EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (09): : 683 - 690
[40] The Potential of Exon Skipping for Treatment for Duchenne Muscular Dystrophy
Partridge, Terence
JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1165 - 1170

← 1 2 3 4 5 →